Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25617747 | 0.93 | L3MBTL1 (0.43) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL25617958 | 0.90 | MEN1 (0.46) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL25618121 | 0.90 | KMT2A (0.42) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL25617616 | 0.89 | KMT2A (0.44) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL25617818 | 0.88 | ALDH1A1 (0.43) | L3MBTL1KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL25617802 | 0.88 | MEN1 (0.45) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL25617820 | 0.86 | TNF (0.40) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL25617813 | 0.85 | MAPT (0.39) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL25617674 | 0.85 | L3MBTL1 (0.49) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL25617793 | 0.85 | ALDH1A1 (0.45) | MEN1KMT2AL3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661404-B2 | Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders | ACHILLES MEDICAL LIMITED (NZ) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661404-B2 | Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders | AKR1C2, AKR1C1, AKR1B1 | MEN1 2592/4885KMT2A 2675/4885L3MBTL1 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.